SPECIALTY QUANTITY LIMIT PROGRAM

NUCALA (mepolizumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Nucala 100 mg single-dose vial	3 per 28 days	 Severe asthma: Age 12 years or older: 100 mg every 4 weeks Age 6 to 11 years: 40 mg every 4 weeks Eosinophilic granulomatosis with polyangiitis: 300 mg (three 100 mg injections) every 4 weeks
Nucala 100 mg/mL single-dose prefilled safety syringe	3 per 28 days	
Nucala 100 mg/mL single-dose prefilled autoinjector	3 per 28 days	

III. REFERENCES

1. Nucala [package insert]. Research Triangle Park, NC: GlaxoSmithKline, Inc.; September 2019.

Specialty Quantity Limit Nucala 2467-H P2019b

 $\ensuremath{\textcircled{}^\circ}$ 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

